Dichotomous Nitric Oxide–Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma

Dichotomous Nitric Oxide–Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma

Although Ipilimumab (anti-CTLA-4) is FDA-approved for stage III/IV melanoma adjuvant treatment, it is not used clinically in first-line therapy, given the superior relapse-free survival (RFS)/toxicity benefits of anti-PD-1 therapy. However, it is important to understand anti-CTLA-4’s mechanistic con...

Full description

Bibliographic Details
Main Authors: Saurabh K. Garg, James Sun, Youngchul Kim, Junmin Whiting, Amod Sarnaik, José R. Conejo-Garcia, Mitch Phelps, Jeffrey S. Weber, James J. Mulé, Joseph Markowitz
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
melanoma
ipilimumab
adjuvant therapy
interferon
post-translational modifications
Online Access:https://www.mdpi.com/2072-6694/15/6/1755

Internet

https://www.mdpi.com/2072-6694/15/6/1755

Similar Items